Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

Science 317 (5834): 121-124

Copyright © 2007 by the American Association for the Advancement of Science

Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production

Willscott E. Naugler,1,2 Toshiharu Sakurai,1 Sunhwa Kim,1 Shin Maeda,3 KyoungHyun Kim,1 Ahmed M. Elsharkawy,1,4 Michael Karin1*

Abstract: Hepatocellular carcinoma (HCC), the most common liver cancer, occurs mainly in men. Similar gender disparity is seen in mice given a chemical carcinogen, diethylnitrosamine (DEN). DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females. Furthermore, ablation of IL-6 abolished the gender differences in hepatocarcinogenesis in mice. DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis. Estrogen inhibited secretion of IL-6 from KCs exposed to necrotic hepatocytes and reduced circulating concentrations of IL-6 in DEN-treated male mice. We propose that estrogen-mediated inhibition of IL-6 production by KCs reduces liver cancer risk in females, and these findings may be used to prevent HCC in males.

1 Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology and Cancer Center, University of California, San Diego, CA 93093, USA.
2 Department of Medicine, Division of Gastroenterology, University of California, San Diego, CA 93093, USA.
3 Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, 1-6-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan.
4 Liver Research Group, University of Newcastle, Newcastle Upon Tyne NE2 4HH, UK.

* To whom correspondence should be addressed: 9500 Gilman Road, Mail Code 0723 University of California, San Diego, San Diego, CA 92093–0636, USA. E-mail: karinoffice{at}

Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a dreaded complication of chronic liver disease that occurs in the setting of risk factors such as hepatitis B (HBV) and hepatitis C (HCV) viral infections, alcoholic liver disease, hemochromatosis, and nonalcoholic steatohepatitis (1). Most HCC appears in cirrhotic livers after years of chronic inflammation. The 5-year survival rate for patients with HCC, the increasing incidence of which is likely due to the spread of HCV (2), is only about 7%. Notably, men are about three to five times more likely to develop HCC than women (3). A similar or even more pronounced gender disparity is seen in rodent HCC models (4, 5). Furthermore, administration of estrogens to male mice inhibits development of chemically (DEN)–induced HCC (6). Nonetheless, the mechanisms that account for this gender disparity and the anticarcinogenic activity of estrogens are unknown.

Inflammation is a major contributing factor to carcinogenesis (7). HCC represents a classic case of inflammation-linked cancer (8), and chemically or genetically induced HCC depends on inflammatory signaling (5, 9, 10). To understand the mechanisms underlying gender disparity in HCC, we used the chemical carcinogen diethylnitrosamine (DEN), which causes HCC in 100% of male mice but only in 10 to 30% of female littermates (5, 6). The pathogenesis of HCC in this mouse model differs from that in humans and thus may not be directly comparable to human HCC. Nevertheless, the mouse model of DEN-induced HCC has a histology and genetic signature similar to that of human HCCs with poor prognosis (11) and recapitulates a dependence on inflammation and gender disparity seen in human HCC.

Interleukin-6 (IL-6) is a multifunctional cytokine largely responsible for the hepatic response to infections or systemic inflammation, oftentermedthe "acute phase response." Concentrations of IL-6 in serum are increased in situations of chronic liver inflammation including alcoholic hepatitis, HBV and HCV infections, and steatohepatitis, conditions that may lead to development of HCC (12). IL-6 concentrations are also increased in patients with HCC relative to normal subjects (13). Whether IL-6 is causal or contributory to HCC is unknown. However, IL-6 is thought to contribute to hepatocyte proliferation (14), and DEN administration to male mice results in IL-6 production that depends on I{kappa}B kinase ß (IKKß) in myeloid cells, most likely the resident liver macrophages called Kupffer cells (KCs). In addition to preventing IL-6 production, ablation of IKKß in myeloid cells prevents compensatory hepatocyte proliferation (5), a response triggered by hepatocyte death.

Compensatory proliferation appears to have a critical role in DEN-induced hepatocarcinogenesis (5, 10), and IL-6 is necessary for normal liver regeneration (14), so we examined gender effects on DEN-induced IL-6 production (15). Administration of DEN resulted in higher amounts of circulating IL-6 in males than in females (Fig. 1A). A similar gender bias was seen for accumulation of IL-6 mRNA in liver (Fig. 1B). Administration of estradiol (E2) to male mice reduced IL-6 mRNA abundance, whereas ovariectomy augmented accumulation of IL-6 mRNA in females. The latter was largely prevented by E2 administration (Fig. 1B), as well as by the estrogen receptor {alpha} (ER{alpha}) agonist propylpyrazole-trisphenol (PPT) (Fig. 1C). No gender differences were seen in IL-6 expression or hepatocyte proliferation after partial hepatectomy (fig. S1, A and B).

Figure 1 Fig. 1.. Differential IL-6 production after chemically induced liver injury. (A) Concentration of IL-6 in serum of male and female WT mice after injection of DEN (100 mg per kg of body weight; n =3 mice per time point). (B) IL-6 mRNA levels in livers of male, female, or ovariectomized (OVX; ovariectomy was done 2 weeks before DEN administration) female mice 4 hours after DEN injection. E2 (50 µg/kg)incornoilwas injected intraperitoneally 2 hours before DEN was administered. (C) Male B6 mice (n =3) were injected with ER{alpha}-specific agonist propyl-pyrazole-trisphenol (PPT; 5 µg/kg in corn oil) 2 hours before DEN injection, and serum IL-6 was measured at the indicated times after DEN injection. Results in (A) to (C) are means ± SE. Asterisks indicate a significant (P < 0.05; Student's t test) difference relative to WT male mice. [View Larger Version of this Image (13K GIF file)]

Pronounced gender-specific differences in IL-6 production were also seen in mice treated with carbon tetrachloride (CCl4), a promoter of HCC development (fig. S2) (16). The cytotoxic effects of DEN and CCl4 are dependent on their metabolic activation within the hepatocyte by cytochrome P450 2E1 (CYP 2E1) (17). Expression of CYP 2E1 did not differ between males and female mice treated with DEN (fig. S3A). Once activated, DEN forms DNA adducts (18). DEN-induced DNA modification and damage should lead to activation of the p53-mediated genomic surveillance response. Indeed, DEN administration led to rapid increase in expression of the p53 target genes p21 and Mdm2, but the response was practically identical in males and females (fig. S3B).

To determine whether the gender bias in IL-6 production accounts for the sex difference in HCC development, we examined DEN-induced hepatocarcinogenesis in male and female IL-6 knockout (IL-6–/–) mice and wild-type (WT) controls. All male WT mice developed HCC, as did 13% of WT females (Fig. 2, A and B). A marked reduction in HCC incidence was seen in IL-6–/– males, whereas no difference was seen between WT and IL-6–/– females. In a cohort of mice monitored for survival, WT male mice exhibited shorter mean survival times than IL-6–/– males or females of either genotype (Fig. 2C).

Figure 2 Fig. 2.. Lower incidence of HCC tumors and longer survival of IL-6–/– mice. (A)Livers of 8-month-old DEN-treated mice. Multiple HCCs are seen only in WT male liver. (B) Incidence of HCC (> 0.5 mm) in WT male (n = 14), WT female (n = 13), IL-6–/– male (n = 14), and IL-6–/– female (n = 15) mice 8 months after DEN (25 mg/kg) injection. Asterisks indicate significant (P < 0.05; Student's t test) differences relative to WT male mice. (C) Survival curves of WT and IL-6–/– mice injected with DEN (25 mg/kg) at 15 days of age (P = 0.0006; log-rank test for significance). [View Larger Version of this Image (41K GIF file)]

We examined the role of IL-6 in gender differences in short-term responses elicited by DEN. Compared to WT animals, IL-6–/– males displayed significantly less hepatic injury after DEN administration as evidenced by reduced alanine aminotransferase (ALT) release (Fig. 3A), less apoptosis (Fig. 3B), and less necrosis (fig. S4A). Differences in compensatory proliferation matched the degree of injury, such that IL-6–/– males exhibited fewer proliferating hepatocytes than WT counterparts at 36 and 48 hours after DEN administration (Fig. 3C). Treatment of male mice with an antagonistic antibody that blocks IL-6 receptor signaling also provided protection from DEN-induced liver injury (fig. S5).

Figure 3 Fig. 3.. Influence of gender and IL-6 on hepatic injury and compensatory proliferation. (A)Male WT or IL-6–/– mice (n = 3) were given DEN (100 mg/kg), and ALT (alanine aminotransferase) in serum was measured. (B) Livers of male WT or IL-6–/– mice (n = 3) were assessed for apoptosis by TUNEL (terminal deoxynucleotidyl transferase– mediated dUTP nick-end labeling) staining after DEN injection. (C) Hepatocyte proliferation in livers of DEN-injected male WT or IL-6–/– mice (n = 3) was assessed by injecting mice with bromodeoxyrudine (BrdU) (1 mg per mouse) 2 hours before the liver was removed. BrdU-positive cells were identified by immunostaining. (D) Serum ALT was measured 48 hours after DEN injection (n = 3 per group). OVX: female mice ovariectomized 2 weeks before DEN administration. E2 (50 µg/kg) in corn oil was injected 2 hours before DEN. Similar studies assessing differences between male and female mice (n = 3) were done for apoptosis (E) and proliferation (F). (G) Six-week-old male B6 mice (n = 3) were given E2 or vehicle (corn oil) 2 hours before DEN injection. Recombinant IL-6 (10 µg) or sham buffer (phosphate-buffered saline) was given subcutaneously at the time of DEN administration. Serum ALT was measured 48 hours later. (H) Male ER{alpha}–/– and ERß–/– mice and littermate heterozygote controls (n = 3) were injected with E2 (50 µg) in corn oil or vehicle 2 hours before DEN injection, and serum ALT was measured 50 hours later. (I)Malemice(n = 3 per point) were injected with PPT (5 mg/kg in corn oil) or vehicle 2 hours before DEN injection, and serum ALT was measured 50 hours later. All results for (A) to (I) are means ± SE, and asterisks indicate P < 0.05 (Student's t test). (J) Cells from livers of male, female, and IL-6–/– mice were lysed at the indicated times after DEN injection. STAT3 and JNK activation, and I{kappa}B{alpha} degradation, were assessed by separating with SDS–polyacrylamide gel electrophoresis and immunoblotting with antibodies to the indicated proteins. Phosphorylation (P) of STAT3 and JNK indicates activation. Phospho-STAT3 and STAT3 were from one gel, as were Phospho-JNK and JNK1/2, and I{kappa}B{alpha} and actin. [View Larger Version of this Image (25K GIF file)]

Consistent with previous publications (19, 20), DEN-induced liver injury was reduced in females or males given E2 2 hours before DEN administration (Fig. 3D). Injury was increased in ovariectomized females and reduced after E2 administration. Absence of IL-6 eliminated gender-related differences by reducing the extent of injury in males (Fig. 3D). DEN-induced apoptosis (Fig. 3E), necrosis (fig. S4B), and compensatory proliferation (Fig. 3F) were greater in male than in female mice. Administration of exogenous IL-6 augmented DEN-induced damage in both untreated and E2-treated male mice (Fig. 3G). The reduction of injury by E2 in IL-6– treated mice suggests that E2 may also attenuate downstream IL-6 signaling. Similar genderrelated differences in liver injury were seen after administration of CCl4 (fig. S2).

Figure 4 Fig. 4.. Requirement of MyD88 for IL-6 production, injury, and hepatocarcinogenesis after DEN treatment. (A)Accumulation of IL-6 mRNA was measured by real-time polymerase chain reaction in KCs from male WT, IKKß–/–, or MyD88–/– mice (n =3 experiments per time point) after incubation with LPS (10 ng/ml) or necrotic debris prepared by cycles of freezethawing of primary hepatocytes. Where indicated, cells were incubated with E2 (10 ng/ml) 30 min before stimulation. (B and C) Male WT and MyD88–/– mice were injected with DEN, and liver IL-6 mRNA (B) or serum ALT (C) was measured. (D and E) Number of HCCs(D) and sizes (E) in livers of WT and MyD88–/– male mice 8 months after DEN (25 mg/kg) administration. Results in (A) to (E) are means ± SE. Asterisks indicate a significant (P <0.05; Student's t test) difference relative to WT males. [View Larger Version of this Image (13K GIF file)]
Using mice deficient in either ER{alpha} or ERß, we found that ER{alpha} is the receptor responsible for the protective effect of E2 (Fig. 3H), which was confirmed by decreased liver injury in male mice pretreated with the ER{alpha}-specific agonist PPT (Fig. 3I).

Another estrogen analog, tamoxifen, was found to act as a weak antagonist in this system and increase liver injury (fig. S6A). Absence of ER{alpha} also increased DEN-induced injury in females (fig. S6A).

IL-6 activates the transcription factor STAT3 (21). The activated form of STAT3 was absent in livers of IL-6–/– mice, and WT female mice exhibited less STAT3 activation than males after DEN administration (Fig. 3J). Female mice or IL-6–/– mice of both genders also exhibited reduced activation of the mitogen-activated protein kinase JNK (c-Jun N-terminal kinase) at 12 hours after DEN administration, whereas little if any difference was seen in DEN-induced I{kappa}B{alpha} degradation. Sustained activation of JNK is required for DEN-induced liver injury as well as hepatocarcinogenesis (5, 10).

Estrogens inhibit IL-6 promoter activity by decreasing the activity of the transcription factors nuclear factor {kappa}B(NF-{kappa}B) and C/EBPß (22). KCs from male mice produced IL-6 when incubated with either bacterial lipopolysaccharide (LPS) or cellular debris released by necrotic hepatocytes (Fig. 4A). Both responses were strongly dependent on IKKß or the Toll-like receptor (TLR) adaptor protein MyD88 and were inhibited if the KCs were first incubated with E2 (Fig. 4A). We speculated that necrotic debris released by DEN-injured hepatocytes triggers cytokine production and compensatory proliferation (5). The TLR adaptor MyD88, which was required for IL-6 induction by necrotic debris, was also required for DEN-induced production of IL-6 in vivo (Fig. 4B) and for induction of liver injury (Fig. 4C). MyD88 was also required for optimal CCl4-induced accumulation of IL-6 mRNA (fig. S7). MyD88 is also required for induction of liver injury in response to hypoxia (23)and LPS (24). Furthermore, MyD88 ablation suppressed DEN-induced hepatocarcinogenesis. MyD88–/– male mice developed fewer (Fig. 4D) and smaller (Fig. 4E) HCC tumors than WT male mice.

Administration of DEN also leads to modest accumulation of tumor necrosis factor–{alpha} (TNF-{alpha}) mRNA (5), another proinflammatory cytokine thought to be involved in liver regeneration (25). However, TNF-{alpha} expression did not exhibit gender-dependent differences (fig. S8A), and ablation of TNF-{alpha} or its type 1 receptor (TNFR1) had little if any effect on production of IL-6 in response to DEN (fig. S8B). Thus, IL-6 induction and liver injury are dependent on signaling via MyD88 but not through TNFR1. Accordingly, ablation of TNFR1 had no significant effect on DEN-induced hepatocarcinogenesis (fig. S8, C and D).

Our results explain why females are less prone to liver cancer than males. This study and others (5, 10) show a strong correlation between the amount of liver damage during acute toxicity and inflammation and the extent of HCC development. We found that both liver injury and compensatory proliferation were strongly dependent on IL-6 and that the absence of this tumor-promoting cytokine resulted in almost complete inhibition of DEN-induced hepatocarcinogenesis. IL-6 production by KCs was largely dependent on MyD88, an adaptor molecule that acts downstream of TLRs as well as IL-1 receptor (26). Because DEN is not a direct macrophage or KC activator (27), hepatocyte necrosis may be an intermediate in the pathway through which DEN or CCl4 exposure results in IL-6 production. Various macromolecules released by necrotic cells activate macrophages through TLRs, the receptors which in turn activate MyD88 (28, 29). TRIF, another TLR adaptor protein (26), is not required for DEN- or CCl4-induced IL-6 production and liver injury (27). MyD88 signaling, but not TNFR1 signaling, was required for optimal DEN-induced hepatocarcinogenesis in male mice. DEN-induced hepatocarcinogenesis appears to depend on an inflammatory response, triggered by hepatocyte necrosis, that leads to production of IL-6. Estrogens, at concentrations present in females but not in males, suppress IL-6 production and therefore inhibit chemically induced liver carcinogenesis. A similar mechanism could account for the gender bias in liver cancer in humans. If so, estrogen-mimetic compounds capable of inhibiting excessive IL-6 production might be used to prevent progression of chronic liver disease to HCC in men.

References and Notes Back to Top

  1. G. Fattovich, T. Stroffolini, I. Zagni, F. Donato, Gastroenterology 127, S35 (2004).[CrossRef] [Web of Science][Medline]
  2. M. Sherman, Semin. Liver Dis. 25, 143 (2005).[CrossRef] [Web of Science][Medline]
  3. F. X. Bosch, J. Ribes, M. Diaz, R. Cleries, Gastroenterology 127, S5 (2004).[CrossRef] [Web of Science][Medline]
  4. N. Ghebranious, S. Sell, Hepatology 27, 383 (1998).[CrossRef] [Web of Science][Medline]
  5. S. Maeda, H. Kamata, J. L. Luo, H. Leffert, M. Karin, Cell 121, 977 (2005).[CrossRef] [Web of Science][Medline]
  6. T. Nakatani, G. Roy, N. Fujimoto, T. Asahara, A. Ito, Jpn. J. Cancer Res. 92, 249 (2001).[CrossRef] [Web of Science][Medline]
  7. F. Balkwill, A. Mantovani, Lancet 357, 539 (2001).[CrossRef] [Web of Science][Medline]
  8. M. Karin, F. R. Greten, Nat. Rev. Immunol. 5, 749 (2005).[CrossRef] [Web of Science][Medline]
  9. E. Pikarsky et al., Nature 431, 461 (2004).[CrossRef][Medline]
  10. T. Sakurai, S. Maeda, L. Chang, M. Karin, Proc. Natl. Acad. Sci. U.S.A. 103, 10544 (2006).[Abstract/Free Full Text]
  11. J. S. Lee et al., Nat. Genet. 36, 1306 (2004).[CrossRef] [Web of Science][Medline]
  12. S. Abiru et al., Liver Int. 26, 39 (2006).[CrossRef][Medline]
  13. M. Soresi et al., World J. Gastroenterol. 12, 2563 (2006). [Web of Science][Medline]
  14. D. E. Cressman et al., Science 274, 1379 (1996).[Abstract/Free Full Text]
  15. Materials and methods are available as supporting material on Science Online.
  16. I. Kovalszky et al., Carcinogenesis 13, 773 (1992).[Abstract/Free Full Text]
  17. L. W. Weber, M. Boll, A. Stampfl, Crit. Rev. Toxicol. 33, 105 (2003). [Web of Science][Medline]
  18. L. Verna, J. Whysner, G. M. Williams, Pharmacol. Ther. 71, 57 (1996).[CrossRef] [Web of Science][Medline]
  19. M. Erikoglu, M. Sahin, S. Ozer, M. C. Avunduk, Surg. Today 35, 467 (2005).[CrossRef] [Web of Science][Medline]
  20. T. Suzuki et al., J. Appl. Physiol. 102, 163 (2007).[Abstract/Free Full Text]
  21. R. Taub, Nat. Rev. Mol. Cell Biol. 5, 836 (2004).[CrossRef] [Web of Science][Medline]
  22. B. Stein, M. X. Yang, Mol. Cell. Biol. 15, 4971 (1995).[Abstract/Free Full Text]
  23. R. Zheng et al., Mol. Med. 12, 65 (2006). [Web of Science][Medline]
  24. A. Velayudham et al., J. Hepatol. 45, 813 (2006).[CrossRef] [Web of Science][Medline]
  25. Y. Yamada, I. Kirillova, J. J. Peschon, N. Fausto, Proc. Natl. Acad. Sci. U.S.A. 94, 1441 (1997).[Abstract/Free Full Text]
  26. S. Akira, S. Uematsu, O. Takeuchi, Cell 124, 783 (2006).[CrossRef] [Web of Science][Medline]
  27. In experiments performed in our laboratory, incubation of KCs or bone marrow–derived macrophages with DEN did not induce expression of IL-6 mRNA. DEN administration to TRIF–/– mice resulted in as much IL-6 induction as seen in WT mice.
  28. M. Karin, T. Lawrence, V. Nizet, Cell 124, 823 (2006).[CrossRef] [Web of Science][Medline]
  29. M. T. Lotze, K. J. Tracey, Nat. Rev. Immunol. 5, 331 (2005).[CrossRef] [Web of Science][Medline]
  30. We thank J. Feramisco for help with image capture and analysis and E. Karin for help with the surgical models. Supported by National Institute of Diabetes and Digestive and Kidney Diseases grant DK007202 (W.E.N.); Japan Society for the Promotion of Science (T.S.); Human Frontier Science Program (S.K.); and NIH grants ES004151 and ES006376, CA118165, and the Superfund Basic Research Program (M.K.). M.K. is an American Cancer Society Professor.

Supporting Online Material

Materials and Methods

Figs. S1 to S8


Received for publication 29 January 2007. Accepted for publication 4 June 2007.

Hepatocellular carcinoma: clinical frontiers and perspectives.
J. Bruix, G. J. Gores, and V. Mazzaferro (2014)
Gut 63, 844-855
   Abstract »    Full Text »    PDF »
Liver Tumor Promotion by 2,3,7,8-Tetrachlorodibenzo-p-dioxin is Dependent on the Aryl Hydrocarbon Receptor and TNF/IL-1 Receptors.
G. D. Kennedy, M. Nukaya, S. M. Moran, E. Glover, S. Weinberg, S. Balbo, S. S. Hecht, H. C. Pitot, N. R. Drinkwater, and C. A. Bradfield (2014)
Toxicol. Sci.
   Abstract »    Full Text »    PDF »
Microphysiological modeling of the reproductive tract: A fertile endeavor.
S. L. Eddie, J. J. Kim, T. K. Woodruff, and J. E. Burdette (2014)
Experimental Biology and Medicine
   Abstract »    Full Text »    PDF »
Computational modeling identifies key gene regulatory interactions underlying phenobarbital-mediated tumor promotion.
R. Luisier, E. B. Unterberger, J. I. Goodman, M. Schwarz, J. Moggs, R. Terranova, and E. van Nimwegen (2014)
Nucleic Acids Res. 42, 4180-4195
   Abstract »    Full Text »    PDF »
Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer.
J. Heijmans, M. C. B. Wielenga, S. L. Rosekrans, J. F. van Lidth de Jeude, J. Roelofs, P. Groothuis, A. Ederveen, E. S. M. de Jonge-Muller, I. Biemond, J. C. H. Hardwick, et al. (2014)
Gut 63, 310-316
   Abstract »    Full Text »    PDF »
MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma.
G. Li, G. Cai, D. Li, and W. Yin (2014)
Postgrad. Med. J. 90, 106-112
   Abstract »    Full Text »    PDF »
Deficiency of the Myeloid Differentiation Primary Response Molecule MyD88 Leads to an Early and Rapid Development of Helicobacter-Induced Gastric Malignancy.
A. Banerjee, S. Thamphiwatana, E. M. Carmona, B. Rickman, K. S. Doran, and M. Obonyo (2014)
Infect. Immun. 82, 356-363
   Abstract »    Full Text »    PDF »
Evaluation of Metabolite Biomarkers for Hepatocellular Carcinoma through Stratified Analysis by Gender, Race, and Alcoholic Cirrhosis.
J. Xiao, Y. Zhao, R. S. Varghese, B. Zhou, C. Di Poto, L. Zhang, M. G. Tadesse, D. H. Ziada, K. Shetty, and H. W. Ressom (2014)
Cancer Epidemiol. Biomarkers Prev. 23, 64-72
   Abstract »    Full Text »    PDF »
Male-Specific W4P/R Mutation in the Pre-S1 Region of Hepatitis B Virus, Increasing the Risk of Progression of Liver Diseases in Chronic Patients.
S.-A. Lee, K.-J. Kim, D.-W. Kim, and B.-J. Kim (2013)
J. Clin. Microbiol. 51, 3928-3936
   PDF »
Role of phosphorylated histone H3 serine 10 in DEN-induced deregulation of Pol III genes and cell proliferation and transformation.
Q. Zhong, G. Shi, Q. Zhang, Y. Zhang, D. Levy, and S. Zhong (2013)
Carcinogenesis 34, 2460-2469
   Abstract »    Full Text »    PDF »
Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription.
B. Xu, S.-H. Li, R. Zheng, S.-B. Gao, L.-H. Ding, Z.-Y. Yin, X. Lin, Z.-J. Feng, S. Zhang, X.-M. Wang, et al. (2013)
PNAS 110, 17480-17485
   Abstract »    Full Text »    PDF »
LIM-Only Protein FHL2 Activates NF-{kappa}B Signaling in the Control of Liver Regeneration and Hepatocarcinogenesis.
J. Dahan, Y. Nouet, G. Jouvion, F. Levillayer, M. Adib-Conquy, A.-M. Cassard-Doulcier, A. Tebbi, F. Blanc, L. Remy, J. Chen, et al. (2013)
Mol. Cell. Biol. 33, 3299-3308
   Abstract »    Full Text »    PDF »
Evidence for a Gender-Specific Protective Role of Innate Immune Receptors in a Model of Perinatal Brain Injury.
P. M. Pimentel-Coelho, J.-P. Michaud, and S. Rivest (2013)
J. Neurosci. 33, 11556-11572
   Abstract »    Full Text »    PDF »
TLR agonists: our best frenemy in cancer immunotherapy.
S. Kaczanowska, A. M. Joseph, and E. Davila (2013)
J. Leukoc. Biol. 93, 847-863
   Abstract »    Full Text »    PDF »
Myeloid Differentiation Factor 88 Promotes Growth and Metastasis of Human Hepatocellular Carcinoma.
B. Liang, R. Chen, T. Wang, L. Cao, Y. Liu, F. Yin, M. Zhu, X. Fan, Y. Liang, L. Zhang, et al. (2013)
Clin. Cancer Res. 19, 2905-2916
   Abstract »    Full Text »    PDF »
Alteration of the Serum N-glycome of Mice Locally Exposed to High Doses of Ionizing Radiation.
T. Chaze, M.-C. Slomianny, F. Milliat, G. Tarlet, T. Lefebvre-Darroman, P. Gourmelon, E. Bey, M. Benderitter, J.-C. Michalski, and O. Guipaud (2013)
Mol. Cell. Proteomics 12, 283-301
   Abstract »    Full Text »    PDF »
Proinflammatory Homeobox Gene, ISX, Regulates Tumor Growth and Survival in Hepatocellular Carcinoma.
S.-H. Hsu, L.-T. Wang, K.-T. Lee, Y.-L. Chen, K.-Y. Liu, J.-L. Suen, C.-Y. Chai, and S.-N. Wang (2013)
Cancer Res. 73, 508-518
   Abstract »    Full Text »    PDF »
MyD88: A Critical Adaptor Protein in Innate Immunity Signal Transduction.
N. Warner and G. Nunez (2013)
J. Immunol. 190, 3-4
   Full Text »    PDF »
p38{alpha} Inhibits Liver Fibrogenesis and Consequent Hepatocarcinogenesis by Curtailing Accumulation of Reactive Oxygen Species.
T. Sakurai, M. Kudo, A. Umemura, G. He, A. M. Elsharkawy, E. Seki, and M. Karin (2013)
Cancer Res. 73, 215-224
   Abstract »    Full Text »    PDF »
Gender Differences in Chemical Carcinogenesis in National Toxicology Program 2-Year Bioassays.
S. Kadekar, S. Peddada, I. Silins, J. E. French, J. Hogberg, and U. Stenius (2012)
Toxicol Pathol 40, 1160-1168
   Abstract »    Full Text »    PDF »
Estrogen Represses Hepatocellular Carcinoma (HCC) Growth via Inhibiting Alternative Activation of Tumor-associated Macrophages (TAMs).
W. Yang, Y. Lu, Y. Xu, L. Xu, W. Zheng, Y. Wu, L. Li, and P. Shen (2012)
J. Biol. Chem. 287, 40140-40149
   Abstract »    Full Text »    PDF »
Resveratrol inhibits LPS-induced epithelial-mesenchymal transition in mouse melanoma model.
M.-C. Chen, W.-W. Chang, Y.-D. Kuan, S.-T. Lin, H.-C. Hsu, and C.-H. Lee (2012)
Innate Immunity 18, 685-693
   Abstract »    Full Text »    PDF »
Does Childhood Misfortune Increase Cancer Risk in Adulthood?.
P. M. Morton, M. H. Schafer, and K. F. Ferraro (2012)
J Aging Health 24, 948-984
   Abstract »    PDF »
The Great Escape: Microbiotal LPS Takes a Toll on the Liver.
D. S. Weiss (2012)
Cancer Prevention Research 5, 1078-1080
   Abstract »    Full Text »    PDF »
The Proinflammatory Myeloid Cell Receptor TREM-1 Controls Kupffer Cell Activation and Development of Hepatocellular Carcinoma.
J. Wu, J. Li, R. Salcedo, N. F. Mivechi, G. Trinchieri, and A. Horuzsko (2012)
Cancer Res. 72, 3977-3986
   Abstract »    Full Text »    PDF »
Context-specific roles for paracrine IL-6 in lymphomagenesis.
L. A. Gilbert and M. T. Hemann (2012)
Genes & Dev. 26, 1758-1768
   Abstract »    Full Text »    PDF »
A Single Neonatal Exposure to Aflatoxin B1 Induces Prolonged Genetic Damage in Two Loci of Mouse Liver.
R. Wattanawaraporn, L. L. Woo, C. Belanger, S.-c. Chang, J. E. Adams, L. J. Trudel, J. T. Bouhenguel, P. A. Egner, J. D. Groopman, R. G. Croy, et al. (2012)
Toxicol. Sci. 128, 326-333
   Abstract »    Full Text »    PDF »
Induction of hepatocellular carcinoma by in vivo gene targeting.
P.-R. Wang, M. Xu, S. Toffanin, Y. Li, J. M. Llovet, and D. W. Russell (2012)
PNAS 109, 11264-11269
   Abstract »    Full Text »    PDF »
Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-{alpha}.
K. Kanda, H. Komekado, T. Sawabu, S. Ishizu, Y. Nakanishi, M. Nakatsuji, R. Akitake-Kawano, M. Ohno, Y. Hiraoka, M. Kawada, et al. (2012)
EMBO Mol Med. 4, 396-411
   Abstract »    Full Text »    PDF »
Inorganic mercury exposure in prairie voles (Microtus ochrogaster) alters the expression of toll-like receptor 4 and activates inflammatory pathways in the liver in a sex-specific manner.
S. Assefa, J. Curtis, S. Sethi, R. Davis, Y. Chen, and R. Kaul (2012)
Human and Experimental Toxicology 31, 376-386
   Abstract »    Full Text »    PDF »
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.
V. Chew, J. Chen, D. Lee, E. Loh, J. Lee, K. H. Lim, A. Weber, K. Slankamenac, R. T. P. Poon, H. Yang, et al. (2012)
Gut 61, 427-438
   Abstract »    Full Text »    PDF »
Metastatic Cells Can Escape the Proapoptotic Effects of TNF-{alpha} through Increased Autocrine IL-6/STAT3 Signaling.
S. Li, N. Wang, and P. Brodt (2012)
Cancer Res. 72, 865-875
   Abstract »    Full Text »    PDF »
Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration.
Y. Shirakami, M. E. Gottesman, and W. S. Blaner (2012)
Carcinogenesis 33, 268-274
   Abstract »    Full Text »    PDF »
2-Amino-3-Methylimidazo[4,5-f]Quinoline (IQ) Promotes Mouse Hepatocarcinogenesis by Activating Transforming Growth Factor-{beta} and Wnt/{beta}-Catenin Signaling Pathways.
X.-L. Xie, M. Wei, A. Kakehashi, S. Yamano, M. Tajiri, and H. Wanibuchi (2012)
Toxicol. Sci. 125, 392-400
   Abstract »    Full Text »    PDF »
Interleukin-11 Links Oxidative Stress and Compensatory Proliferation.
T. Nishina, S. Komazawa-Sakon, S. Yanaka, X. Piao, D.-M. Zheng, J.-H. Piao, Y. Kojima, S. Yamashina, E. Sano, T. Putoczki, et al. (2012)
Science Signaling 5, ra5
   Abstract »    Full Text »    PDF »
JNK-Induced Apoptosis, Compensatory Growth, and Cancer Stem Cells.
F. Chen (2012)
Cancer Res. 72, 379-386
   Abstract »    Full Text »    PDF »
CUEDC2 (CUE Domain-containing 2) and SOCS3 (Suppressors of Cytokine Signaling 3) Cooperate to Negatively Regulate Janus Kinase 1/Signal Transducers and Activators of Transcription 3 Signaling.
W.-N. Zhang, L. Wang, Q. Wang, X. Luo, D.-F. Fang, Y. Chen, X. Pan, J.-H. Man, Q. Xia, B.-F. Jin, et al. (2012)
J. Biol. Chem. 287, 382-392
   Abstract »    Full Text »    PDF »
A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis.
R. Zaynagetdinov, T. P. Sherrill, V. V. Polosukhin, W. Han, J. A. Ausborn, A. G. McLoed, F. B. McMahon, L. A. Gleaves, A. L. Degryse, G. T. Stathopoulos, et al. (2011)
J. Immunol. 187, 5703-5711
   Abstract »    Full Text »    PDF »
CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer.
L. Zhang, R. Rahbari, M. He, and E. Kebebew (2011)
Endocr. Relat. Cancer 18, 731-742
   Abstract »    Full Text »    PDF »
Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice.
R. S. Scotland, M. J. Stables, S. Madalli, P. Watson, and D. W. Gilroy (2011)
Blood 118, 5918-5927
   Abstract »    Full Text »    PDF »
Evolution of the TIR Domain-Containing Adaptors in Humans: Swinging between Constraint and Adaptation.
S. Fornarino, G. Laval, L. B. Barreiro, J. Manry, E. Vasseur, and L. Quintana-Murci (2011)
Mol. Biol. Evol. 28, 3087-3097
   Abstract »    Full Text »    PDF »
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer.
J. Coward, H. Kulbe, P. Chakravarty, D. Leader, V. Vassileva, D. A. Leinster, R. Thompson, T. Schioppa, J. Nemeth, J. Vermeulen, et al. (2011)
Clin. Cancer Res. 17, 6083-6096
   Abstract »    Full Text »    PDF »
Human serum N-glycan profiles are age and sex dependent.
N. Ding, H. Nie, X. Sun, W. Sun, Y. Qu, X. Liu, Y. Yao, X. Liang, C. C. Chen, and Y. Li (2011)
Age Ageing 40, 568-575
   Abstract »    Full Text »    PDF »
Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis.
J. Kluwe, N. Wongsiriroj, J. S. Troeger, G.-Y. Gwak, D. H. Dapito, J.-P. Pradere, H. Jiang, M. Siddiqi, R. Piantedosi, S. M. O'Byrne, et al. (2011)
Gut 60, 1260-1268
   Abstract »    Full Text »    PDF »
CXCR3 Enhances a T-Cell-Dependent Epidermal Proliferative Response and Promotes Skin Tumorigenesis.
A. E. Winkler, J. J. Brotman, M. E. Pittman, N. P. Judd, J. S. Lewis Jr, R. D. Schreiber, and R. Uppaluri (2011)
Cancer Res. 71, 5707-5716
   Abstract »    Full Text »    PDF »
Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth.
P. Hojman, C. Dethlefsen, C. Brandt, J. Hansen, L. Pedersen, and B. K. Pedersen (2011)
Am J Physiol Endocrinol Metab 301, E504-E510
   Abstract »    Full Text »    PDF »
17{beta}-Estradiol and Tamoxifen Prevent Gastric Cancer by Modulating Leukocyte Recruitment and Oncogenic Pathways in Helicobacter Pylori-Infected INS-GAS Male Mice.
A. Sheh, Z. Ge, N. M. A. Parry, S. Muthupalani, J. E. Rager, A. R. Raczynski, M. W. Mobley, A. F. McCabe, R. C. Fry, T. C. Wang, et al. (2011)
Cancer Prevention Research 4, 1426-1435
   Abstract »    Full Text »    PDF »
miR-22 Promotes HBV-Related Hepatocellular Carcinoma Development in Males.
R. Jiang, L. Deng, L. Zhao, X. Li, F. Zhang, Y. Xia, Y. Gao, X. Wang, and B. Sun (2011)
Clin. Cancer Res. 17, 5593-5603
   Abstract »    Full Text »    PDF »
The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis.
R. M. Bigsby and A. Caperell-Grant (2011)
Carcinogenesis 32, 1162-1166
   Abstract »    Full Text »    PDF »
Chemotherapeutic Resistance: Surviving Stressful Situations.
L. A. Gilbert and M. T. Hemann (2011)
Cancer Res. 71, 5062-5066
   Abstract »    Full Text »    PDF »
Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor-Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells.
Y. Liu, A. Liu, H. Li, C. Li, and J. Lin (2011)
Cancer Prevention Research 4, 1296-1305
   Abstract »    Full Text »    PDF »
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.
M. Jinushi, S. Chiba, H. Yoshiyama, K. Masutomi, I. Kinoshita, H. Dosaka-Akita, H. Yagita, A. Takaoka, and H. Tahara (2011)
PNAS 108, 12425-12430
   Abstract »    Full Text »    PDF »
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data.
Y. Tao, J. Ruan, S.-H. Yeh, X. Lu, Y. Wang, W. Zhai, J. Cai, S. Ling, Q. Gong, Z. Chong, et al. (2011)
PNAS 108, 12042-12047
   Abstract »    Full Text »    PDF »
Aflatoxin B1-DNA Adduct Formation and Mutagenicity in Livers of Neonatal Male and Female B6C3F1 Mice.
L. L. Woo, P. A. Egner, C. L. Belanger, R. Wattanawaraporn, L. J. Trudel, R. G. Croy, J. D. Groopman, J. M. Essigmann, and G. N. Wogan (2011)
Toxicol. Sci. 122, 38-44
   Abstract »    Full Text »    PDF »
HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis.
Z. C. Hartman, X.-Y. Yang, O. Glass, G. Lei, T. Osada, S. S. Dave, M. A. Morse, T. M. Clay, and H. K. Lyerly (2011)
Cancer Res. 71, 4380-4391
   Abstract »    Full Text »    PDF »
Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses.
M. B. Davis, D. Vasquez-Dunddel, J. Fu, E. Albesiano, D. Pardoll, and Y. J. Kim (2011)
Clin. Cancer Res. 17, 3984-3992
   Abstract »    Full Text »    PDF »
Chronic Inflammatory IFN-{gamma} Signaling Suppresses Hepatocarcinogenesis in Mice by Sensitizing Hepatocytes for Apoptosis.
S. Luth, J. Schrader, S. Zander, A. Carambia, J. Buchkremer, S. Huber, K. Reifenberg, K.-I. Yamamura, P. Schirmacher, A. W. Lohse, et al. (2011)
Cancer Res. 71, 3763-3771
   Abstract »    Full Text »    PDF »
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion.
R. D. Schreiber, L. J. Old, and M. J. Smyth (2011)
Science 331, 1565-1570
   Abstract »    Full Text »    PDF »
The role of JNK in the development of hepatocellular carcinoma.
M. Das, D. S. Garlick, D. L. Greiner, and R. J. Davis (2011)
Genes & Dev. 25, 634-645
   Abstract »    Full Text »    PDF »
Preventive Effects of (-)-Epigallocatechin Gallate on Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-db/db Mice.
M. Shimizu, H. Sakai, Y. Shirakami, Y. Yasuda, M. Kubota, D. Terakura, A. Baba, T. Ohno, Y. Hara, T. Tanaka, et al. (2011)
Cancer Prevention Research 4, 396-403
   Abstract »    Full Text »    PDF »
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.
S. I. Grivennikov and M. Karin (2011)
Ann Rheum Dis 70, i104-i108
   Abstract »    Full Text »    PDF »
Interleukin 6, but Not T Helper 2 Cytokines, Promotes Lung Carcinogenesis.
C. E. Ochoa, S. G. Mirabolfathinejad, V. A. Ruiz, S. E. Evans, M. Gagea, C. M. Evans, B. F. Dickey, and S. J. Moghaddam (2011)
Cancer Prevention Research 4, 51-64
   Abstract »    Full Text »    PDF »
Acyclic Retinoid Inhibits Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BLKS/J- +Leprdb/+Leprdb Mice.
M. Shimizu, H. Sakai, Y. Shirakami, J. Iwasa, Y. Yasuda, M. Kubota, K. Takai, H. Tsurumi, T. Tanaka, and H. Moriwaki (2011)
Cancer Prevention Research 4, 128-136
   Abstract »    Full Text »    PDF »
Isoflurane activates intestinal sphingosine kinase to protect against bilateral nephrectomy-induced liver and intestine dysfunction.
M. Kim, S. W. Park, M. Kim, V. D. D'Agati, and H. T. Lee (2011)
Am J Physiol Renal Physiol 300, F167-F176
   Abstract »    Full Text »    PDF »
gp130 at the nexus of inflammation, autoimmunity, and cancer.
J. S. Silver and C. A. Hunter (2010)
J. Leukoc. Biol. 88, 1145-1156
   Abstract »    Full Text »    PDF »
Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer.
Cancer Genomics Proteomics 7, 287-302
   Abstract »    Full Text »    PDF »
Sexually Dimorphic Actions of Glucocorticoids Provide a Link to Inflammatory Diseases with Gender Differences in Prevalence.
D. Duma, J. B. Collins, J. W. Chou, and J. A. Cidlowski (2010)
Science Signaling 3, ra74
   Abstract »    Full Text »    PDF »
B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses.
P.-Y. Lin, L. Sun, S. R. Thibodeaux, S. M. Ludwig, R. K. Vadlamudi, V. J. Hurez, R. Bahar, M. J. Kious, C. B. Livi, S. R. Wall, et al. (2010)
J. Immunol. 185, 2747-2753
   Abstract »    Full Text »    PDF »
Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells.
Y. Liu, P.-K. Li, C. Li, and J. Lin (2010)
J. Biol. Chem. 285, 27429-27439
   Abstract »    Full Text »    PDF »
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18.
R. Salcedo, A. Worschech, M. Cardone, Y. Jones, Z. Gyulai, R.-M. Dai, E. Wang, W. Ma, D. Haines, C. O'hUigin, et al. (2010)
J. Exp. Med. 207, 1625-1636
   Abstract »    Full Text »    PDF »
Estrogen Receptors and Endothelium.
J.-F. Arnal, C. Fontaine, A. Billon-Gales, J. Favre, H. Laurell, F. Lenfant, and P. Gourdy (2010)
Arterioscler Thromb Vasc Biol 30, 1506-1512
   Abstract »    Full Text »    PDF »
Apoptosis-promoted tumorigenesis: {gamma}-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death.
E. M. Michalak, C. J. Vandenberg, A. R. D. Delbridge, L. Wu, C. L. Scott, J. M. Adams, and A. Strasser (2010)
Genes & Dev. 24, 1608-1613
   Abstract »    Full Text »    PDF »
TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.
D. Mittal, F. Saccheri, E. Venereau, T. Pusterla, M. E. Bianchi, and M. Rescigno (2010)
EMBO J. 29, 2242-2252
   Abstract »    Full Text »    PDF »
Ontogenetic Complexity of Sexual Dimorphism and Sex-Specific Selection.
J. E. Mank, K. Nam, B. Brunstrom, and H. Ellegren (2010)
Mol. Biol. Evol. 27, 1570-1578
   Abstract »    Full Text »    PDF »
Toll-Like Receptor 6 Ser249Pro Polymorphism Is Associated With Lower Left Ventricular Wall Thickness and Inflammatory Response in Hypertensive Women.
M. L. Sales, R. Schreiber, M. C. S. Ferreira-Sae, M. N. Fernandes, C. S. C. Piveta, J. A. A. Cipolli, C. C. Cardoso, J. R. Matos-Souza, B. Geloneze, K. G. Franchini, et al. (2010)
Am J Hypertens 23, 649-654
   Abstract »    Full Text »    PDF »
Resveratrol Suppresses Oxidative Stress and Inflammatory Response in Diethylnitrosamine-Initiated Rat Hepatocarcinogenesis.
A. Bishayee, K. F. Barnes, D. Bhatia, A. S. Darvesh, and R. T. Carroll (2010)
Cancer Prevention Research 3, 753-763
   Abstract »    Full Text »    PDF »
Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.
M. K. Connolly, J. Mallen-St. Clair, A. S. Bedrosian, A. Malhotra, V. Vera, J. Ibrahim, J. Henning, H. L. Pachter, D. Bar-Sagi, A. B. Frey, et al. (2010)
J. Leukoc. Biol. 87, 713-725
   Abstract »    Full Text »    PDF »
Toll-like Receptor 3-Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance.
A. I. Chin, A. K. Miyahira, A. Covarrubias, J. Teague, B. Guo, P. W. Dempsey, and G. Cheng (2010)
Cancer Res. 70, 2595-2603
   Abstract »    Full Text »    PDF »
Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases.
S. Danese and B. Gao (2010)
Gut 59, 149-151
   Full Text »    PDF »
CADPE Suppresses Cyclin D1 Expression in Hepatocellular Carcinoma by Blocking IL-6-induced STAT3 Activation.
C. WON, C. S. LEE, J.-K. LEE, T.-J. KIM, K.-H. LEE, Y. M. YANG, Y.-N. KIM, S.-K. YE, and M.-H. CHUNG (2010)
Anticancer Res 30, 481-488
   Abstract »    Full Text »    PDF »
Nuclear Factor-{kappa}B and Tumor-Associated Macrophages.
A. Mancino and T. Lawrence (2010)
Clin. Cancer Res. 16, 784-789
   Abstract »    Full Text »    PDF »
Roles for Inflammation and Regulatory T Cells in Colon Cancer.
S. E. Erdman and T. Poutahidis (2010)
Toxicol Pathol 38, 76-87
   Abstract »    Full Text »    PDF »
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens.
J G Fox, Y Feng, E J Theve, A R Raczynski, J L A Fiala, A L Doernte, M Williams, J L McFaline, J M Essigmann, D B Schauer, et al. (2010)
Gut 59, 88-97
   Abstract »    Full Text »    PDF »
The Aryl Hydrocarbon Receptor Functions as a Tumor Suppressor of Liver Carcinogenesis.
Y. Fan, G. P. Boivin, E. S. Knudsen, D. W. Nebert, Y. Xia, and A. Puga (2010)
Cancer Res. 70, 212-220
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882